It is feasible and effective to help patients with severe mental disorders to quit smoking: an ecological pragmatic clinical trial with transdermal nicotine patches and …
MP Garcia-Portilla, L Garcia-Alvarez, F Sarramea… - Schizophrenia …, 2016 - Elsevier
Despite the proven association between smoking and high rates of medical morbidity and
reduced life expectancy in people with severe mental disorders (SMD), their smoking rates
do not decline as they do in the general population. We carried out a non-randomized, open-
label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy,
safety and tolerability of a 12-week smoking cessation programme for patients with SMD in
the community under real-world clinical conditions. Eighty-two adult outpatients with …
reduced life expectancy in people with severe mental disorders (SMD), their smoking rates
do not decline as they do in the general population. We carried out a non-randomized, open-
label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy,
safety and tolerability of a 12-week smoking cessation programme for patients with SMD in
the community under real-world clinical conditions. Eighty-two adult outpatients with …
Is it feasible and effective to help patients with severe mental disorders to quit smoking?
J Bobes - European Psychiatry, 2017 - cambridge.org
Despite the proven association between smoking and high rates of medical morbidity and
reduced life expectancy in people with severe mental disorders (SMD), their smoking rates
do not decline as they do in the general population. We carried out a non-randomized, open-
label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy,
safety and tolerability of a smoking cessation programme designed for the treatment of
patients with SMD in the community under real-world clinical conditions. A total of 82 …
reduced life expectancy in people with severe mental disorders (SMD), their smoking rates
do not decline as they do in the general population. We carried out a non-randomized, open-
label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy,
safety and tolerability of a smoking cessation programme designed for the treatment of
patients with SMD in the community under real-world clinical conditions. A total of 82 …
以上显示的是最相近的搜索结果。 查看全部搜索结果